QUOTED. 9 September 2020. Nick West.
Executive Summary
Abbott has launched a clinical trial of the Esprit BTK everolimus-eluting resorbable scaffold to treat arteries below the knee. See what Abbott Vascular Chief Medical Officer Nick West had to say.
“Far too many people are impacted by peripheral artery disease, and this new drug-eluting resorbable scaffold is needed to offer meaningful improvements in how this disease is treated.”– Nick West, chief medical officer, Abbott Vascular
- Find out more: Abbott Launches Trial Of First-Of-A-Kind Resorbable Scaffold For Critical Limb Ischemia
Click here for a free trial of Medtech Insight